WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 156

Legislative bill overview

HB 156 relates to intranasal epinephrine, a medication administered through the nose to treat severe allergic reactions (anaphylaxis). The bill was introduced in the Kentucky House in January 2026 and is currently in the Health Services Committee. The specific provisions are not detailed in the available information, but such bills typically address access, distribution, training, or liability protections for this life-saving medication.

Why is this important

Intranasal epinephrine offers an alternative to traditional injectable epinephrine auto-injectors (EpiPens), potentially improving accessibility for people with severe allergies, asthma, and food allergies. Expanding distribution mechanisms—such as placing devices in schools, public spaces, or allowing lay administrators to dispense them—could increase survival rates during anaphylactic emergencies. Kentucky's legislation could serve as a model for other states managing medication accessibility and emergency response protocols.

Potential points of contention

  • Public access vs. medical oversight: Balancing broader availability of intranasal epinephrine with proper medical training and oversight to prevent misuse or inappropriate administration
  • Cost and funding: Determining who bears the expense of purchasing and maintaining intranasal epinephrine supplies in public locations
  • Liability protection: Questions about legal immunity for schools, businesses, and lay responders who administer the medication in good faith during emergencies

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.